Table 2 Clinical characteristics of P. micra in case series, and in the literature cases
Characteristic | Patients [no. (%) or as indicated] with: | ||
|---|---|---|---|
Our case series (25) | Literature cases (27) | ||
Age | yr: median (range) | 83.0 (58–92) | 59.0 (23–94) |
Gender | No.male/no.famale (ratio) | 14/11 (1.3) | 15/12 (1.3) |
Community onset/nosocomial | 23/2 | 26/1 | |
Method of pathogen detection | MALDI-TOF MS | 23 | 6 |
16S rRNA sequencing | 0 | 3 | |
Biochemical test | 2 | 4 | |
Gas chromatography | 0 | 6 | |
Symptom | Fever, no. (%) | 23 (92.0) | 12 (44.4) |
Headache, no. (%) | 0 | 2 (7.4) | |
Pharyngeal symptoms, no. (%) | 1 (4.0) | 0 | |
Shortness of breath, no. (%) | 0 | 2 (7.4) | |
Abdominal symptoms, no. (%) | 1 (4.0) | 3 (11.1) | |
Vomiting, no. (%) | 1 (4.0) | 1 (3.7) | |
Diarrhea, no. (%) | 1 (4.0) | 0 | |
Myalgia, no. (%) | 0 | 4 (14.8) | |
Shaking and/or chill, no. (%) | 9 (36.0) | 4 (14.8) | |
Low back pain, no. (%) | 0 | 6 (22.2) | |
Underlying health status | Steroid usage, no. (%) | 1 (4.0) | 0 |
Diabetes, no. (%) | 6 (24.0) | 3 (11.1) | |
Heart valve replacement, no. (%) | 0 | 2 (7.4) | |
Malignancies, no. (%) | 9 (36.0) | 3 (11.1) | |
Diverticular disease, no. (%) | 1 (4.0) | 1 (3.7) | |
Abdominal operation within 4 weeks, no. (%) | 1 (4.0) | 0 | |
Gastrointestinal perforation, no. (%) | 1 (4.0) | 0 | |
Gynecologic disease, no. (%) | 0 | 3 (11.1) | |
Charlson comorbidity score, median (range) | 5 (0–7) | N/Ra | |
Focus or likely source of infection | Meningitis, no. (%) | 0 | 1 (3.7) |
Oropharyngeal, no. (%) | 7 (28.0) | 7 (25.9) | |
Endocarditis, no. (%) | 0 | 3 (11.1) | |
Lung, no. (%) | 1 (4.0) | 0 | |
Septic pulmonary emboli, no. (%) | 1 (4.0) | 3 (11.1) | |
Hepatobiliary (liver, pancreas, gallbladder, biliary), no. (%) | 1 (4.0) | 1 (3.7) | |
Gastrointestinal tract, no. (%) | 6 (24.0) | 3 (11.1) | |
Intraabdominal abscess, no. (%) | 0 | 4 (14.8) | |
Pylephlebitis, no. (%) | 0 | 2 (7.4) | |
Spondylodiscitis, no. (%) | 1 (4.0) | 8 (29.6) | |
Bacteremia with unknown source, no. (%) | 9 (36.0) | 4 (14.8) | |
Polymicrobial bacteremia | no. (%) | 12/25 (48) | 5/27 (18.5) |
Pitt bacteremia score | median (range) | 1 (0–13) | N/R |
Antibiotic sensitivity testing b | Penicillin, no. (%) | 22/22 (100) b | 10/10 (100) |
Ampicillin-sulbactam, no. (%) | 12/12 (100) b | 4/4 (100) | |
Piperacillin-tazobactam, no. (%) | 12/12 (100) b | 5/5 (100) | |
Meropenem, no. (%) | 19/19 (100) b | 5/5 (100) | |
Clindamycin, no. (%) | 13/15 (86.7) b | 9/9 (100) | |
All-cause mortality at: | 30 days, no. (%) | 1/25 (4.0) | 1/27 (3.7) |